Trial Profile
An Open, Single-arm, Multi-center Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALTER-L020
- 01 Apr 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 01 Apr 2020 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2021.
- 01 Apr 2020 Status changed from not yet recruiting to recruiting.